Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:15198132rdf:typepubmed:Citationlld:pubmed
pubmed-article:15198132lifeskim:mentionsumls-concept:C0018546lld:lifeskim
pubmed-article:15198132lifeskim:mentionsumls-concept:C0030231lld:lifeskim
pubmed-article:15198132pubmed:issue3lld:pubmed
pubmed-article:15198132pubmed:dateCreated2004-6-16lld:pubmed
pubmed-article:15198132pubmed:abstractTextHaloperidol is one of 20 'essential' medications in palliative care. Its use is widespread in palliative care patients. The pharmacology of haloperidol is complex and the extent and severity of some of its adverse effects, particularly extrapyramidal adverse effects (EPS), may be related to the route of administration. Indications for the use of haloperidol in palliative care are nausea and vomiting and delirium. Adverse effects include EPS and QT prolongation. Sedation is not a common adverse effect of haloperidol. It is important that palliative care practitioners have a comprehensive understanding of the indications, doses, adverse effects and pharmacology of haloperidol. This review is intended to address these issues.lld:pubmed
pubmed-article:15198132pubmed:languageenglld:pubmed
pubmed-article:15198132pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15198132pubmed:citationSubsetIMlld:pubmed
pubmed-article:15198132pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15198132pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15198132pubmed:statusMEDLINElld:pubmed
pubmed-article:15198132pubmed:monthAprlld:pubmed
pubmed-article:15198132pubmed:issn0269-2163lld:pubmed
pubmed-article:15198132pubmed:authorpubmed-author:MacleodA DADlld:pubmed
pubmed-article:15198132pubmed:authorpubmed-author:Vella-Brincat...lld:pubmed
pubmed-article:15198132pubmed:issnTypePrintlld:pubmed
pubmed-article:15198132pubmed:volume18lld:pubmed
pubmed-article:15198132pubmed:ownerNLMlld:pubmed
pubmed-article:15198132pubmed:authorsCompleteYlld:pubmed
pubmed-article:15198132pubmed:pagination195-201lld:pubmed
pubmed-article:15198132pubmed:dateRevised2005-11-16lld:pubmed
pubmed-article:15198132pubmed:meshHeadingpubmed-meshheading:15198132...lld:pubmed
pubmed-article:15198132pubmed:meshHeadingpubmed-meshheading:15198132...lld:pubmed
pubmed-article:15198132pubmed:meshHeadingpubmed-meshheading:15198132...lld:pubmed
pubmed-article:15198132pubmed:meshHeadingpubmed-meshheading:15198132...lld:pubmed
pubmed-article:15198132pubmed:meshHeadingpubmed-meshheading:15198132...lld:pubmed
pubmed-article:15198132pubmed:meshHeadingpubmed-meshheading:15198132...lld:pubmed
pubmed-article:15198132pubmed:meshHeadingpubmed-meshheading:15198132...lld:pubmed
pubmed-article:15198132pubmed:meshHeadingpubmed-meshheading:15198132...lld:pubmed
pubmed-article:15198132pubmed:year2004lld:pubmed
pubmed-article:15198132pubmed:articleTitleHaloperidol in palliative care.lld:pubmed
pubmed-article:15198132pubmed:affiliationNurse Maude Hospice, Christchurch, New Zealand. janevb@cdhb.govt.nzlld:pubmed
pubmed-article:15198132pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:15198132pubmed:publicationTypeReviewlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15198132lld:pubmed